Carmignac Gestion Corcept Therapeutics Inc Transaction History

Carmignac Gestion

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$22.21 - $34.48 $51,460 - $79,890	2,317 Added 13.68%	19,260 $625,000
Q1 2024 May 14, 2024	SELL	$21.1 - $27.46 $187,304 - $243,762	-8,877 Reduced 34.38%	16,943 $426,000
Q3 2023 Nov 13, 2023	SELL	$21.97 - $33.8 $439,400 - $676,000	-20,000 Reduced 43.65%	25,820 $703,000
Q1 2023 May 12, 2023	SELL	$19.2 - $24.47 $283,353 - $361,128	-14,758 Reduced 24.36%	45,820 $992,000
Q4 2022 Feb 13, 2023	BUY	$19.95 - $29.96 $1.21 Million - $1.81 Million	60,578 New	60,578 $1.23 Million

403

84.3M

1.04M

1.33M

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $5.87B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Carmignac Gestion, based on Form 13F filings with the SEC.

Stay updated on Carmignac Gestion with notifications on news.